$244.32
0.76% day before yesterday
NYSE, Nov 01, 09:00 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Target price 2024 - Analyst rating & recommendation

ResMed Classifications & Recommendation:

Buy
67%
Hold
29%
Sell
4%

ResMed Price Target

Target Price $258.88
Price $244.28
Potential
Number of Estimates 17
17 Analysts have issued a price target ResMed 2025 . The average ResMed target price is $258.88. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 24 analysts: 16 Analysts recommend ResMed to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ResMed stock has an average upside potential 2025 of . Most analysts recommend the ResMed stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '24 2025
Estimates
Revenue Billion $ 4.69 5.12
10.95% 9.23%
EBITDA Margin 34.16% 36.09%
6.96% 5.66%
Net Margin 21.68% 25.83%
2.42% 19.15%

20 Analysts have issued a sales forecast ResMed 2025 . The average ResMed sales estimate is

$5.1b
Unlock
. This is
6.45% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$5.2b 8.62%
Unlock
, the lowest is
$5.0b 4.68%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $4.7b 10.95%
2025
$5.1b 9.23%
Unlock
2026
$5.5b 7.37%
Unlock
2027
$5.9b 7.29%
Unlock
2028
$6.3b 6.16%
Unlock
2029
$6.8b 9.20%
Unlock

16 Analysts have issued an ResMed EBITDA forecast 2025. The average ResMed EBITDA estimate is

$1.8b
Unlock
. This is
8.71% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$1.9b 14.33%
Unlock
, the lowest is
$1.6b 3.84%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $1.6b 18.67%
2025
$1.8b 15.40%
Unlock
2026
$2.0b 9.14%
Unlock
2027
$2.2b 8.50%
Unlock
2028
$2.2b 0.95%
Unlock
2029
$2.2b 0.15%
Unlock

EBITDA Margin

2024 34.16% 6.96%
2025
36.09% 5.66%
Unlock
2026
36.68% 1.63%
Unlock
2027
37.09% 1.12%
Unlock
2028
35.27% 4.91%
Unlock
2029
32.35% 8.28%
Unlock

16 ResMed Analysts have issued a net profit forecast 2025. The average ResMed net profit estimate is

$1.3b
Unlock
. This is
19.43% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.4b 27.29%
Unlock
, the lowest is
$1.2b 7.56%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $1.0b 13.63%
2025
$1.3b 30.13%
Unlock
2026
$1.5b 11.01%
Unlock
2027
$1.6b 9.25%
Unlock
2028
$1.7b 7.64%
Unlock
2029
$1.9b 11.22%
Unlock

Net Margin

2024 21.68% 2.42%
2025
25.83% 19.15%
Unlock
2026
26.70% 3.37%
Unlock
2027
27.19% 1.84%
Unlock
2028
27.57% 1.40%
Unlock
2029
28.08% 1.85%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Jun '24 2025
Estimates
Earnings Per Share $ 6.92 9.00
13.63% 30.06%
P/E 27.13
EV/Sales 7.09

16 Analysts have issued a ResMed forecast for earnings per share. The average ResMed <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$9.00
Unlock
. This is
19.36% higher
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$9.60 27.32%
Unlock
, the lowest is
$8.11 7.56%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $6.92 13.63%
2025
$9.00 30.06%
Unlock
2026
$10.00 11.11%
Unlock
2027
$10.92 9.20%
Unlock
2028
$11.76 7.69%
Unlock
2029
$13.08 11.22%
Unlock

P/E ratio

Current 32.38 47.85%
2025
27.13 16.21%
Unlock
2026
24.44 9.92%
Unlock
2027
22.37 8.47%
Unlock
2028
20.78 7.11%
Unlock
2029
18.68 10.11%
Unlock

Based on analysts' sales estimates for 2025, the ResMed stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.55 56.64%
2025
7.09 6.10%
Unlock
2026
6.60 6.87%
Unlock
2027
6.15 6.80%
Unlock
2028
5.80 5.80%
Unlock
2029
5.31 8.43%
Unlock

P/S ratio

Current 7.46 64.78%
2025
7.01 6.06%
Unlock
2026
6.53 6.87%
Unlock
2027
6.08 6.79%
Unlock
2028
5.73 5.80%
Unlock
2029
5.25 8.43%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today